Companies / Tyra Biosciences, Inc.
Tyra Biosciences, Inc.
Nasdaq: TYRACIK 1863127CARLSBAD, CA
Financials
Ownership
59.7M shares outstanding · as of Jul 31, 2026
Ownership
| Insiders | 2.32% | 1,386,862 |
| Institutions | 100.97% | 60,254,418 |
| Public float | 0.00% | 0 |
Reported holdings exceed shares outstanding — public float shown as 0; some positions may overlap or lag.
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 10
View all →| Insider | % of shares | Shares |
|---|---|---|
Todd HarrisCEOPresident and CEO · Director | 2.28% | 1,358,631 |
Bensen DanielFormerChief Discovery Officer | 0.25% | 146,981 |
Fuhrman AlanFormerChief Financial Officer | 0.06% | 36,164 |
Kaplan GillaDirector | 0.05% | 28,231 |
Kolchinsky PeterFormerDirector · 10% owner | — | — |
More Robert JDirector | — | — |
RA Capital Healthcare Fund LPFormerDirector · 10% owner | — | — |
RA Capital Management, L.P.FormerDirector · 10% owner | — | — |
RA Capital Nexus Fund, L.P.FormerDirector | — | — |
Shah Rajeev M.FormerDirector · 10% owner | — | — |
Institutional holders 142
View all →| Holder | Value | % of shares |
|---|---|---|
| $467.21M | 20.44% | |
| $148.87M | 6.52% | |
| $106.63M | 6.80% | |
| $100.52M | 6.41% | |
| $96.84M | 5.08% | |
| $88.73M | 5.66% | |
| $88.71M | 5.65% | |
| $76.19M | 4.86% | |
| $75.69M | 3.31% | |
| $68.36M | 3.59% |
Activity
InsidersInstitutions
What insiders are doing in this stock (Form 4).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | Kaplan Gilla Director | Other | Common Stock | $2.01M | -53K -65.32% | 28,231 0.05% of shares | low |
| Mar 25, 2026 | Kaplan Gilla Director | Sell | Common Stock | $528.5K | -14K -33.61% | 28,231 0.05% of shares | medium |
| Jan 12, 2026 | Bensen Daniel Executive | Sell | Common Stock | $198.6K | -7K -4.28% | 155,998 0.26% of shares | medium |
| Feb 12, 2026 | Bensen Daniel Executive | Sell | Common Stock | $195.9K | -6K -3.84% | 146,981 0.25% of shares | medium |
| Mar 26, 2026 | Kaplan Gilla Director | Exercise | Common Stock | $119.6K | -53K -39.51% | 81,403 0.14% of shares | low |
| Feb 12, 2026 | Bensen Daniel Executive | Sell | Common Stock | $67.0K | -2K -1.37% | 152,853 0.26% of shares | low |
| Mar 25, 2026 | Kaplan Gilla Director | Exercise | Common Stock | $32.2K | +14K +50.64% | 42,526 0.07% of shares | low |
| Jan 12, 2026 | Bensen Daniel Executive | Sell | Common Stock | $29.6K | -1K -0.65% | 154,981 0.26% of shares | low |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Farallon Capital Partners, L.P. | Passive13G | — |
| Todd Harris | Passive13G | — |
| Canaan XI L.P. | Passive13G/A | — |
| Biotechnology Value Fund L P | Passive13G/A | — |
| Farallon Capital Partners, L.P. | Passive13G/A | — |
| Janus Henderson Group PLC | Passive13G/A | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| TYRA | — | 90240B106 |